<DOC>
	<DOC>NCT00564018</DOC>
	<brief_summary>To determine whether using a long-acting insulin analog at the time of diagnosis, instead of intermediate-acting insulin, affects the rate of loss of the body's ability to make insulin in children with newly diagnosed type 1 diabetes.</brief_summary>
	<brief_title>Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Newly diagnosed type 1 diabetes within 1 week of diagnosis Age 6 18 years Care provided at Children's Medical Center, Dallas Actual treatment with oral drugs influencing beta cell function or blood glucose levels (e.g. oral hypoglycemic agents) Actual treatment with drugs influencing insulin sensitivity (e.g. Metformin, or systemic steroids) Significant concomitant disease likely to interfere with glucose metabolism (children with active bacterial infections at the time of diagnosis must be cured prior to entry) Expected poor compliance Pregnancy Any other condition that by the judgement of the investigator may be potentially harmful to the patients</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>type 1 diabetes, basal-bolus, honeymoon, C-peptide</keyword>
</DOC>